Astec LifeSciences Limited — Important, 27-01-2025: General Updates

**Company Announcements:**

The Board has approved the unaudited financial results for the quarter and nine months ended 31st December, 2024. The results show a revenue from operations of ₹93.86 crore, leading to a total income of ₹95.77 crore. However, the company reported a net loss of ₹40.36 crore for the quarter, compared to losses of ₹38.55 crore in the previous quarter.

In governance updates, Mr. R. R. Govindan has been re-appointed as a Non-Executive & Independent Director for a term from 30th January, 2025, to 12th August, 2029, pending shareholder approval via postal ballot.

The Board has also approved an equity investment of up to ₹3.75 crore in a proposed Special Purpose Vehicle with Clean Max Enviro Energy for renewable power generation.

Lastly, Mr. Arijit Mukherjee, Chief Operating Officer, has been granted 831 stock options under the Employee Stock Option Plan.